Abstract

Mitochondrial quality control is critical for cardiac homeostasis as these organelles are responsible for generating most of the energy needed to sustain contraction. Dysfunctional mitochondria are normally degraded via intracellular degradation pathways that converge on the lysosome. Here, we identified an alternative mechanism to eliminate mitochondria when lysosomal function is compromised. We show that lysosomal inhibition leads to increased secretion of mitochondria in large extracellular vesicles (EVs). The EVs are produced in multivesicular bodies, and their release is independent of autophagy. Deletion of the small GTPase Rab7 in cells or adult mouse heart leads to increased secretion of EVs containing ubiquitinated cargos, including intact mitochondria. The secreted EVs are captured by macrophages without activating inflammation. Hearts from aged mice or Danon disease patients have increased levels of secreted EVs containing mitochondria indicating activation of vesicular release during cardiac pathophysiology. Overall, these findings establish that mitochondria are eliminated in large EVs through the endosomal pathway when lysosomal degradation is inhibited.

Mitochondrial quality control is critical for cellular homeostasis and survival. Here, the authors identify that defective mitochondria can be eliminated via secretion in large extracellular vesicles when internal lysosomal degradation is compromised.

Details

Title
Mitochondria are secreted in extracellular vesicles when lysosomal function is impaired
Author
Liang, Wenjing 1 ; Sagar, Shakti 1 ; Ravindran, Rishith 1 ; Najor, Rita H. 1 ; Quiles, Justin M. 1 ; Chi, Liguo 1 ; Diao, Rachel Y. 1 ; Woodall, Benjamin P. 1 ; Leon, Leonardo J. 1 ; Zumaya, Erika 1 ; Duran, Jason 2 ; Cauvi, David M. 3 ; De Maio, Antonio 3 ; Adler, Eric D. 2 ; Gustafsson, Åsa B. 4   VIAFID ORCID Logo 

 University of California San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242) 
 University of California San Diego, Department of Medicine, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242) 
 University of California San Diego, Department of Surgery, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242) 
 University of California San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); University of California San Diego, Department of Pharmacology, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242) 
Pages
5031
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2852874244
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.